Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
Open Access
- 20 February 2024
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 5 (4) , 100656
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2019
- Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)Cancer, 2019
- A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancerJournal of Cerebral Blood Flow & Metabolism, 2019
- NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018Journal of the National Comprehensive Cancer Network, 2018
- Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutationsOncotarget, 2017
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityClinical Cancer Research, 2016
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsCancer Discovery, 2015
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersLung Cancer, 2015
- Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancerCancer Letters, 2014
- A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling TimesTherapeutic Drug Monitoring, 2009